The former is an inhibitor of tropomyosin receptor kinase (TRK) A (TRKA), TRKB, and TRKC, which has been evaluated in two phase I trials and one phase II basket trial, including 26 patients with thyroid cancer (22%). This evidence concerns the gene NTRK2 and thyroid gland carcinoma.